bluebird bio (BLUE) Stock Forecast, Price Target & Predictions
BLUE Stock Forecast
bluebird bio stock forecast is as follows: an average price target of $13.69 (represents a 62.78% upside from BLUE’s last price of $8.41) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
BLUE Price Target
The average price target for bluebird bio (BLUE) is $13.69 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $5.00. This represents a potential 62.78% upside from BLUE's last price of $8.41.
BLUE Analyst Ratings
According to 4 Wall Street analysts, bluebird bio's rating consensus is 'Hold'. The analyst rating breakdown for BLUE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 2 'Hold' (50.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
bluebird bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 22, 2022 | Gena Wang | Barclays | $5.00 | $5.83 | -14.16% | -40.55% |
| Mar 07, 2022 | David Nierengarten | Wedbush | $6.48 | $2.88 | 125.00% | -22.95% |
| Nov 19, 2021 | Cory Kasimov | J.P. Morgan | $14.00 | $10.70 | 30.84% | 66.47% |
| Nov 12, 2021 | Zhiqiang Shu | Berenberg Bank | $11.00 | $11.68 | -5.82% | 30.80% |
| Nov 08, 2021 | Salveen Richter | Goldman Sachs | $10.00 | $10.70 | -6.54% | 18.91% |
| Sep 13, 2021 | Joshua Schimmer | Evercore ISI | $25.00 | $11.84 | 111.15% | 197.27% |
| Aug 10, 2021 | John Newman | Canaccord Genuity | $20.00 | $12.97 | 54.20% | 137.81% |
| Aug 09, 2021 | Benjamin Burnett | Stifel Nicolaus | $18.00 | $11.76 | 53.06% | 114.03% |
The latest bluebird bio stock forecast, released on Aug 22, 2022 by Gena Wang from Barclays, set a price target of $5.00, which represents a -14.16% decrease from the stock price at the time of the forecast ($5.83), and a -40.55% decrease from BLUE last price ($8.41).
bluebird bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $8.41 | $8.41 | $8.41 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of bluebird bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to bluebird bio's last price of $8.41. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 25, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 25, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Aug 15, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 15, 2024 | Barclays | Underperform | Underperform | Hold |
| Aug 15, 2024 | Oppenheimer | Perform | Perform | Hold |
| Mar 27, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Mar 27, 2024 | Wedbush | Underperform | Underperform | Hold |
| Dec 15, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Jul 19, 2023 | Wedbush | Neutral | Buy | Upgrade |
| Jun 01, 2023 | Barclays | Equal-Weight | Overweight | Upgrade |
| Aug 22, 2022 | Barclays | Equal-Weight | Upgrade | |
| Aug 22, 2022 | William Blair | Market Perform | Market Perform | Hold |
| Aug 17, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Aug 01, 2022 | Raymond James | Outperform | Upgrade | |
| Jun 13, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| Mar 07, 2022 | Wedbush | Neutral | Neutral | Hold |
bluebird bio's last stock rating was published by RBC Capital on Sep 25, 2024. The company gave BLUE a "Underperform" rating, the same as its previous rate.
bluebird bio Financial Forecast
bluebird bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.39M | $6.89M | $2.38M | $62.00K | $71.00K | $1.52M | $1.95M | $-39.28M | $22.68M | $7.47M | $12.79M | $10.71M | $19.27M | $198.89M | $21.86M | $10.00M | $8.91M |
| Avg Forecast | $115.74M | $108.53M | $94.95M | $90.22M | $85.26M | $78.52M | $58.83M | $37.72M | $26.08M | $18.05M | $24.25M | $19.26M | $16.78M | $13.56M | $11.30M | $6.52M | $1.05M | $1.07M | $824.17K | $187.50K | $5.08M | $37.21M | $16.28M | $11.55M | $14.65M | $24.32M | $76.46M | $7.58M | $9.17M | $11.38M |
| High Forecast | $145.20M | $136.16M | $119.13M | $113.19M | $106.97M | $98.51M | $73.81M | $43.63M | $27.81M | $22.65M | $24.25M | $19.59M | $20.64M | $13.60M | $14.18M | $8.19M | $1.31M | $1.07M | $824.17K | $187.50K | $5.08M | $37.21M | $16.28M | $11.55M | $14.65M | $24.32M | $76.46M | $7.58M | $9.17M | $11.38M |
| Low Forecast | $82.97M | $77.80M | $68.07M | $64.68M | $61.13M | $56.29M | $42.17M | $34.02M | $23.84M | $12.94M | $24.25M | $18.93M | $11.63M | $13.52M | $8.10M | $4.68M | $749.29K | $1.07M | $824.17K | $187.50K | $5.08M | $37.21M | $16.28M | $11.55M | $14.65M | $24.32M | $76.46M | $7.58M | $9.17M | $11.38M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.61% | 0.36% | 0.06% | 0.07% | 1.84% | 10.37% | -7.73% | 0.61% | 0.46% | 1.11% | 0.73% | 0.79% | 2.60% | 2.88% | 1.09% | 0.78% |
bluebird bio's average Quarter revenue forecast for Dec 23 based on 7 analysts is $16.78M, with a low forecast of $11.63M, and a high forecast of $20.64M. BLUE's average Quarter revenue forecast represents a 35.44% increase compared to the company's last Quarter revenue of $12.39M (Sep 23).
bluebird bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-84.73M | $-85.30M | $-84.49M | $25.43M | $-88.18M | $-92.78M | $-119.33M | $-153.24M | $-210.63M | $-235.05M | $-199.67M | $-193.36M | $-187.50M | $-13.97M | $-192.28M | $-211.23M | $-193.33M |
| Avg Forecast | $-115.74M | $-108.53M | $-94.95M | $-90.22M | $-85.26M | $-78.52M | $-58.83M | $-37.72M | $-26.08M | $-18.05M | $-24.25M | $-85.33M | $-16.78M | $-13.56M | $-11.30M | $-91.26M | $-206.14M | $-1.07M | $-824.17K | $-97.61M | $-5.08M | $-37.21M | $-16.28M | $-195.69M | $-14.65M | $-24.32M | $-76.46M | $-210.02M | $-9.17M | $-11.38M |
| High Forecast | $-82.97M | $-77.80M | $-68.07M | $-64.68M | $-61.13M | $-56.29M | $-42.17M | $-34.02M | $-23.84M | $-12.94M | $-24.25M | $-68.26M | $-11.63M | $-13.52M | $-8.10M | $-73.01M | $-164.91M | $-1.07M | $-824.17K | $-78.09M | $-5.08M | $-37.21M | $-16.28M | $-156.55M | $-14.65M | $-24.32M | $-76.46M | $-168.02M | $-9.17M | $-11.38M |
| Low Forecast | $-145.20M | $-136.16M | $-119.13M | $-113.19M | $-106.97M | $-98.51M | $-73.81M | $-43.63M | $-27.81M | $-22.65M | $-24.25M | $-102.40M | $-20.64M | $-13.60M | $-14.18M | $-109.52M | $-247.37M | $-1.07M | $-824.17K | $-117.13M | $-5.08M | $-37.21M | $-16.28M | $-234.83M | $-14.65M | $-24.32M | $-76.46M | $-252.03M | $-9.17M | $-11.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.25% | 7.55% | 0.93% | -0.12% | 82.09% | 112.57% | 1.22% | 30.15% | 5.66% | 14.44% | 1.02% | 13.20% | 7.71% | 0.18% | 0.92% | 23.04% | 16.99% |
3 analysts predict BLUE's average Quarter EBITDA for Mar 23 to be $-91.26M, with a high of $-73.01M and a low of $-109.52M. This is -458.81% lower than bluebird bio's previous annual EBITDA (Dec 22) of $25.43M.
bluebird bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-71.73M | $-72.91M | $34.04M | $32.23M | $-76.52M | $-92.88M | $-123.96M | $101.69M | $-216.82M | $-241.70M | $-205.81M | $-199.87M | $-194.75M | $-21.46M | $-202.61M | $-223.35M | $-206.03M |
| Avg Forecast | $348.04M | $298.60M | $193.89M | $148.52M | $22.80M | $-58.63M | $-336.08M | $-650.51M | $-1.16B | $-1.41B | $-1.62B | $-86.05M | $-2.55B | $-2.59B | $-2.73B | $-92.03M | $-213.08M | $-216.41M | $-251.19M | $-98.42M | $-381.68M | $-307.48M | $-409.97M | $-201.71M | $-372.44M | $-382.72M | $-301.73M | $-221.31M | $-475.02M | $-446.36M |
| High Forecast | $463.23M | $397.42M | $258.07M | $197.68M | $30.35M | $-37.05M | $-212.40M | $-325.26M | $-858.02M | $-892.40M | $-1.02B | $-68.84M | $670.04M | $-1.64B | $-1.73B | $-73.62M | $-170.47M | $-216.41M | $-251.19M | $-78.74M | $-381.68M | $-307.48M | $-409.97M | $-161.36M | $-372.44M | $-382.72M | $-301.73M | $-177.04M | $-475.02M | $-446.36M |
| Low Forecast | $219.96M | $188.71M | $122.54M | $93.86M | $14.41M | $-78.04M | $-447.32M | $-894.45M | $-1.33B | $-1.88B | $-2.15B | $-103.25M | $-4.38B | $-3.45B | $-3.64B | $-110.43M | $-255.70M | $-216.41M | $-251.19M | $-118.11M | $-381.68M | $-307.48M | $-409.97M | $-242.05M | $-372.44M | $-382.72M | $-301.73M | $-265.57M | $-475.02M | $-446.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 0.03% | -0.37% | -0.15% | 0.35% | 0.37% | 1.26% | -0.27% | 0.71% | 0.59% | 1.02% | 0.54% | 0.51% | 0.07% | 0.92% | 0.47% | 0.46% |
bluebird bio's average Quarter net income forecast for Jun 23 is $-2.73B, with a range of $-3.64B to $-1.73B. BLUE's average Quarter net income forecast represents a -8132.99% decrease compared to the company's last Quarter net income of $34.04M (Mar 23).
bluebird bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.70M | $40.35M | $37.35M | $30.71M | $33.40M | $36.69M | $36.11M | $-19.74M | $68.28M | $78.58M | $86.87M | $76.97M | $68.05M | $68.63M | $73.25M | $76.20M | $66.25M |
| Avg Forecast | $2.51B | $2.35B | $2.06B | $1.95B | $1.85B | $1.70B | $1.27B | $816.53M | $564.48M | $390.73M | $524.98M | $416.96M | $363.29M | $293.52M | $244.66M | $141.23M | $22.62M | $23.25M | $17.84M | $4.06M | $110.03M | $805.36M | $352.41M | $249.99M | $317.17M | $526.51M | $1.66B | $164.07M | $198.49M | $246.30M |
| High Forecast | $3.14B | $2.95B | $2.58B | $2.45B | $2.32B | $2.13B | $1.60B | $944.38M | $601.95M | $490.21M | $524.99M | $424.13M | $446.83M | $294.41M | $306.95M | $177.19M | $28.38M | $23.25M | $17.84M | $4.06M | $110.03M | $805.36M | $352.41M | $249.99M | $317.17M | $526.51M | $1.66B | $164.07M | $198.49M | $246.30M |
| Low Forecast | $1.80B | $1.68B | $1.47B | $1.40B | $1.32B | $1.22B | $912.90M | $736.29M | $515.96M | $280.12M | $524.98M | $409.78M | $251.68M | $292.64M | $175.40M | $101.25M | $16.22M | $23.25M | $17.84M | $4.06M | $110.03M | $805.36M | $352.41M | $249.99M | $317.17M | $526.51M | $1.66B | $164.07M | $198.49M | $246.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.14% | 0.16% | 0.26% | 1.36% | 1.44% | 2.06% | 8.90% | -0.18% | 0.08% | 0.22% | 0.35% | 0.24% | 0.13% | 0.04% | 0.45% | 0.38% | 0.27% |
bluebird bio's average Quarter SG&A projection for Dec 23 is $363.29M, based on 7 Wall Street analysts, with a range of $251.68M to $446.83M. The forecast indicates a 792.53% rise compared to BLUE last annual SG&A of $40.70M (Sep 23).
bluebird bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.66 | $-0.67 | $0.33 | $0.38 | $-0.94 | $-1.26 | $-1.68 | $1.40 | $-3.16 | $-3.58 | $-3.07 | $-3.01 | $-2.94 | $-0.36 | $-3.64 | $-4.04 | $-3.73 |
| Avg Forecast | $1.79 | $1.54 | $1.00 | $0.77 | $0.12 | $-0.30 | $-1.73 | $-3.35 | $-5.96 | $-7.28 | $-8.33 | $-8.82 | $-13.13 | $-13.37 | $-14.10 | $-7.39 | $-6.58 | $-1.12 | $-1.30 | $-1.45 | $-1.97 | $-1.59 | $-2.12 | $-1.95 | $-1.92 | $-1.98 | $-1.56 | $-2.62 | $-2.45 | $-2.30 |
| High Forecast | $2.39 | $2.05 | $1.33 | $1.02 | $0.16 | $-0.19 | $-1.10 | $-1.68 | $-4.43 | $-4.60 | $-5.27 | $-5.58 | $3.46 | $-8.45 | $-8.91 | $-4.67 | $-4.16 | $-1.12 | $-1.30 | $-1.45 | $-1.97 | $-1.59 | $-2.12 | $-1.95 | $-1.92 | $-1.98 | $-1.56 | $-2.62 | $-2.45 | $-2.30 |
| Low Forecast | $1.13 | $0.97 | $0.63 | $0.48 | $0.07 | $-0.40 | $-2.31 | $-4.61 | $-6.84 | $-9.69 | $-11.09 | $-11.74 | $-22.58 | $-17.80 | $-18.77 | $-9.84 | $-8.76 | $-1.12 | $-1.30 | $-1.45 | $-1.97 | $-1.59 | $-2.12 | $-1.95 | $-1.92 | $-1.98 | $-1.56 | $-2.62 | $-2.45 | $-2.30 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | 0.05% | -0.04% | -0.06% | 0.84% | 0.97% | 1.16% | -0.71% | 1.99% | 1.69% | 1.57% | 1.57% | 1.49% | 0.23% | 1.39% | 1.65% | 1.62% |
According to 6 Wall Street analysts, bluebird bio's projected average Quarter EPS for Jun 23 is $-14.10, with a low estimate of $-18.77 and a high estimate of $-8.91. This represents a -4373.95% decrease compared to BLUE previous annual EPS of $0.33 (Mar 23).
bluebird bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| KPTI | Karyopharm Therapeutics | $0.67 | $7.33 | 994.03% | Buy |
| CVAC | CureVac | $2.95 | $29.00 | 883.05% | Buy |
| VIR | Vir Bio | $7.35 | $28.00 | 280.95% | Buy |
| YMAB | Y-mAbs Therapeutics | $9.53 | $22.50 | 136.10% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.13 | $7.00 | 123.64% | Buy |
| VKTX | Viking Therapeutics | $46.70 | $97.80 | 109.42% | Buy |
| BLUE | bluebird bio | $8.97 | $13.69 | 52.62% | Hold |
| SRPT | Sarepta Therapeutics | $125.76 | $187.20 | 48.85% | Buy |
| MRSN | Mersana Therapeutics | $2.03 | $3.00 | 47.78% | Buy |
| AGIO | Agios Pharmaceuticals | $41.96 | $53.50 | 27.50% | Buy |
| TVTX | Travere Therapeutics | $17.14 | $21.75 | 26.90% | Buy |
| KRYS | Krystal Biotech | $169.04 | $210.33 | 24.43% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| PTCT | PTC Therapeutics | $47.02 | $48.00 | 2.08% | Hold |